@profleandro182's BPC-157 and TB-500 claims, fact-checked

What does this video actually claim?

Prof Leandro Moscardi tells his 18.6K viewers that BPC-157 and TB-500 are two distinct regenerative peptides with different mechanisms. He describes BPC-157 as a 15-amino acid fragment that works locally on tendons, ligaments, and muscles.

Meanwhile, he positions TB-500 as a systemic peptide that stimulates cell migration and angiogenesis. The video promises to explain their biochemical mechanisms, practical applications, and dosing protocols.

Does the science actually support these peptide benefits?

Here's where things get sketchy. Most BPC-157 research comes from rodent studies, not human trials. A 2020 systematic review by Park et al. found promising results in rat models for tendon healing, but acknowledged the lack of human clinical data.

TB-500 research is even thinner. While thymosin beta-4 (the full protein) has been studied in humans for wound healing, TB-500 specifically lacks strong clinical trials. The FDA hasn't approved either peptide for therapeutic use.

Both peptides exist in a regulatory gray area. They're sold as research chemicals, not medications.

What did the creator get wrong about these peptides?

Moscardi treats these peptides like proven therapies when they're experimental at best. He doesn't mention that BPC-157 isn't naturally found in human gastric juice, despite claims about it being a "gastric peptide."

The dosing information he provides is problematic because there are no established therapeutic doses for humans. Most dosing protocols are extrapolated from animal studies or anecdotal reports from biohackers.

He also glosses over safety concerns. A 2022 case report documented cardiac issues in a patient using BPC-157, though causation wasn't definitively established.

What's the real deal with peptide regulation?

The FDA has been cracking down on compounding pharmacies selling these peptides. In 2022, they sent warning letters to several facilities for marketing unapproved peptide therapies.

Neither BPC-157 nor TB-500 appears on the FDA's approved drug list. They can't legally be prescribed as medications in the United States. Some compounding pharmacies still offer them, but this exists in a legal gray zone.

The World Anti-Doping Agency banned TB-500 in 2010 after athletes used it for performance enhancement. That should tell you something about its regulatory status.

What should you actually know about these peptides?

If you're considering peptide therapy, understand that you're essentially participating in an uncontrolled experiment. The long-term safety data simply doesn't exist for human use.

The animal studies are intriguing but don't guarantee human efficacy or safety. Remember thalidomide worked fine in animal studies.

Work with a physician who understands peptide therapy's limitations and legal status. Don't get your medical advice from TikTok, even from accounts with "Prof" in the name. The platform's algorithm rewards engagement, not accuracy.